ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
-0.26%
US Tech 100
19,167.60
0.00%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.37401
-0.08%
Bitcoin
66,087.31
-0.83%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTA)

  7. Pasithea Therapeutics Corporation (KTTA) News

KTTA

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KTTA
DateTimeSourceHeadlineSymbolCompany
06/13/20245:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
05/28/20245:59AMGlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
04/29/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
04/24/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/01/20248:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/13/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
01/18/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
01/08/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
01/02/20243:47PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
01/02/20247:35AMGlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
12/28/20234:00PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
12/28/20234:00PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
12/28/202310:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
12/19/20234:26PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
12/19/20234:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
12/19/20234:19PMGlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
12/11/20237:01AMGlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
11/29/20234:00PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
11/29/20233:27PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
11/29/20236:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
11/13/20233:45PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
11/09/20236:59AMGlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
10/26/20234:01PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTA

Your Recent History

USOTC
CNNA
Cann American (CE)
USOTC
HHSE
Hannover House (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
RONN
Ronn Motor (PK)
NASDAQ
COOP
Mr Cooper
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
CIVX
CTR Investments and Cons... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
SMCE
SMC Entertainment (PK)
USOTC
SPZI
Spooz (PK)
NASDAQ
DJT
Trump Media and Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved